Navigation Links
Oncothyreon highlights corporate and clinical objectives for 2008
Date:1/28/2008

synthetic MUC1-based liposomal glycolipopeptide cancer vaccine that utilizes Oncothyreon's proprietary adjuvant PET-lipid A, and PX-316, a small molecule inhibitor of AKT-mediated survival signaling. The Company is also seeking partners for its proprietary adjuvants, as well as for a group of small molecules with potential applications in restenosis. In addition, Oncothyreon continues to evaluate external product development opportunities.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to payments Oncothyreon may expect to receive; manufacturing and other costs; the therapeutic and commercial potential of Stimuvax and other product candidates; future clinical development plans for various product candidates; the details of the clinical trials for various product candidates; the anticipated future size of the market for Stimuvax; and identifying and capitalizing on possible collaboration, strategic partnering, acquisition or divestiture opportunities. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Biomira announces plan to change name to Oncothyreon
2. Highlights of Economic and Business Growth in the Tampa Bay Region
3. Highlights of Economic and Business Growth in the Tampa Bay Region
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
6. Highlights of Economic and Business Growth in the Tampa Bay Region
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
9. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
10. Biomoda, Inc. Retains MicroCap Management, LLC as its Lead Corporate Communications and Broker Relations Firm.
11. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... July 29, 2015  AsureQuality and Ubiquitome have ... for applications in food and primary production sectors. ... real-time PCR device, the Freedom4. AsureQuality ... to the supermarket shelf for producers, processors and ... in animal disease control and pest management and ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... 20 Inverness Medical,Innovations, Inc. (Amex: IMA ), ... its financial results for the quarter,ended December 31, 2007., ... recorded net revenue of,$288.0 million compared to net revenue ... revenue increase was primarily due to increased,product sales in ...
... OSTE ), a leader in the emerging field of ... for the year,ending December 31, 2007 increased 5% to ... December 31, 2006. Revenue from "core" product,lines, DBM and ... increase of 15% over core product revenue of $58.8 ...
... Today at 10:00 CET, AMSTERDAM, February 20 Amsterdam Molecular,Therapeutics ... reported its full year 2007 results., Highlights ... - Cash & cash equivalents of EUR 51.3 million at ... lead product AMT 011 - Positive results of Phase I/II ...
Cached Biology Technology:Inverness Medical Innovations Announces Fourth Quarter 2007 Results 2Inverness Medical Innovations Announces Fourth Quarter 2007 Results 3Inverness Medical Innovations Announces Fourth Quarter 2007 Results 4Inverness Medical Innovations Announces Fourth Quarter 2007 Results 5Inverness Medical Innovations Announces Fourth Quarter 2007 Results 6Inverness Medical Innovations Announces Fourth Quarter 2007 Results 7Inverness Medical Innovations Announces Fourth Quarter 2007 Results 8Inverness Medical Innovations Announces Fourth Quarter 2007 Results 9Inverness Medical Innovations Announces Fourth Quarter 2007 Results 10Inverness Medical Innovations Announces Fourth Quarter 2007 Results 11Inverness Medical Innovations Announces Fourth Quarter 2007 Results 12Inverness Medical Innovations Announces Fourth Quarter 2007 Results 13Inverness Medical Innovations Announces Fourth Quarter 2007 Results 14Inverness Medical Innovations Announces Fourth Quarter 2007 Results 15Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 2Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 3Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 4Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 5Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 2Amsterdam Molecular Therapeutics Reports Full Year Results 2007 3Amsterdam Molecular Therapeutics Reports Full Year Results 2007 4Amsterdam Molecular Therapeutics Reports Full Year Results 2007 5Amsterdam Molecular Therapeutics Reports Full Year Results 2007 6Amsterdam Molecular Therapeutics Reports Full Year Results 2007 7
(Date:7/23/2015)... , July 23, 2015 Research ... addition of the "Global Outlook of the ... offering. The global biometrics market ... public and commercial applications owing to the uptake ... witness a transformation that enhances the growth of ...
(Date:7/20/2015)... DENVER , July 20, 2015  Acuity ... Mobility Report: The Convergence of Commerce and Privacy" ... billion mobile biometric apps will be downloaded to ... users. The mobile biometrics market is projected to ... app revenue during the seven-year forecast period.    ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... HILO, HawaiiA team of scientists from the ... and two universities will begin research using sophisticated ... that have the most potential for ecological restoration. ... Susan Cordell, PSW research ecologist; Dr. Erin Questad, ...
... Jan. 24, 2012 Ingenuity Systems, a leading ... science researchers, today announced the general availability of ... fastest way to get biological meaning from expression ... for the statistical analysis and biological interpretation of ...
... recent Van Andel Research Institute (VARI) study published in the journal ... essential plant hormone could profoundly change our understanding of a key ... drugs for a variety of diseases. The study builds ... that was published in the journal Nature in 2009. ...
Cached Biology News:High-tech models help guide restoration efforts to save threatened plants 2Ingenuity Systems iReport Now Available: Fast, Accurate, Interactive Report for Gene Expression Data 2
... PrecisION Ion Channel Cell Lines ,High Quality, ... channels are well known for having a ... and consequently have a key function in ... modulate ion channels have been investigated in ...
... PrecisION Ion Channel Cell Lines ,High ... ,Ion channels are well known for having ... function and consequently have a key function ... that modulate ion channels have been investigated ...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
Biology Products: